Senseonics Posts 87% Revenue Surge on Eversense 365 Momentum
Event summary
- Q1 2026 revenue hit $11.7M, up 87% YoY, driven by Eversense 365 adoption
- Raised $100M+ in equity/debt to fuel global expansion and pipeline
- Launched Eversense 365 in Europe with first insertions in Sweden
- U.S. direct-to-consumer marketing boosted new patient adds by ~100% YoY
- Full-year revenue guidance raised to $60M-$64M (prior $58M-$62M)
The big picture
Senseonics' 87% revenue surge reflects accelerating adoption of its long-term implantable CGM systems, particularly Eversense 365. The company's strategic shift to full commercial control—both in the U.S. and now Europe—positions it to compete more directly with Dexcom and Abbott in the automated insulin delivery ecosystem. With $100M+ in fresh capital, the key question is whether Senseonics can scale manufacturing and sales infrastructure fast enough to meet its ambitious 70%-82% full-year growth target.
What we're watching
- Commercial Execution
- Whether Senseonics can sustain 87% revenue growth as it transitions European commercialization in-house from Ascensia.
- Product Pipeline
- The pace at which Gemini and Freedom systems advance through development, given $100M+ in new funding.
- Market Penetration
- How European launch timing and uptake will affect full-year revenue guidance of $60M-$64M.